Search our team at AdventHealth Research Institute
Showing 1 - 3 of 3 clinical trials matching your search
-
NCT06282575
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis is an open-label, randomized, multicenter, phase 3 study to investigate the efficacy and safety of zanidatamab plus CisGem with or without a PD-1/L1 inhibitor (physician’s choice of either...
-
NCT05822752
M24-147: A Phase 2, Randomized Open-Label Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine the optimal dose of livmoniplimab and to determine if livmoniplimab in combination with budigalimab is safe and effective at treating locally advanced or...
-
NCT05904886
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)
This study is not currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this...